Request Demo
Recent blog posts
Latest Hotspot
8 min read
Recombinant oncolytic virus M1(Guangzhou Vitron) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Recombinant oncolytic virus M1(Guangzhou Vitron): Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Eftilagimod alpha Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Eftilagimod alpha: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Dravet Syndrome Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Dravet Syndrome clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
Spinal Muscular Atrophy Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Spinal Muscular Atrophy clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
GS-100 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
GS-100: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Duchenne Muscular Dystrophy Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Duchenne Muscular Dystrophy clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white…
Latest Hotspot
8 min read
Anti-VEGF humanized monoclonal antibody(Jiangsu T-Mab Biopharma Co.,Ltd) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Anti-VEGF humanized monoclonal antibody(Jiangsu T-Mab Biopharma Co.,Ltd): Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers.
Latest Hotspot
8 min read
Multiple System Atrophy Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Multiple System Atrophy clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
AQW-051 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
AQW-051: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Progressive Supranuclear Palsy Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Progressive Supranuclear Palsy clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development…
Latest Hotspot
8 min read
Lewy Body Dementia Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Lewy Body Dementia clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
Trastuzumab biosimilar(Genor Biopharma Co., Ltd.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
GB221 (GEMMABio): Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.